Theravance, Inc. - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Theravance, Inc.. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Theravance, Inc.. The Group's principal activity is that of a biopharmaceutical company with a pipeline of internally discovered product candidates. It focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Its programs include: telavancin for the treatment of serious Gram-positive bacterial infections with Astellas Pharma Inc. and Horizon program and the Bifunctional Muscarinic Antagonist-beta2 Agonist program with GlaxoSmithKline PLC.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report